Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 37-44

  Petrara, Maria Raffaella ^a,b   Giunco, Silvia ^b   Serraino, Diego ^a   Dolcetti, Riccardo ^a   De Rossi, Anita ^b,c  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

EBV; Inflammation immune activation; Latent lytic viral cycle; PTLD; Telomerase; Treatment

Indexed keywords

DOXORUBICIN; FLUOROURACIL; GANCICLOVIR; HISTONE DEACETYLASE INHIBITOR; LATENT MEMBRANE PROTEIN 1; METHOTREXATE; RITUXIMAB; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADOPTIVE TRANSFER; CARCINOGENESIS; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MALIGNANT TRANSFORMATION; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; VIROLOGY; VIRUS LATENCY;

ANIMALS; ANTIVIRAL AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TELOMERASE; VIRUS LATENCY;

EID: 84943408583     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.007     Document Type: Review

References (89)

1. Starzl T.E., Porter K.A., Iwatsuki S., Rosenthal J.T., Shaw B.W., Atchison R.W., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587.
2. Morscio J., Dierickx D., Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?. Clin. Dev. Immunol 2013, 2013:150835.
3. Global Observatory on Donation and Transplantation Global observatory on donation and transplantation data, produced by the WHO-ONT collaboration accessed 31.3.15. http://www.transplant-observatory.org.
4. Vajdic C.M., McDonald S.P., McCredie M.R., van Leeuwen M.T., Stewart J.H., Law M., et al. Cancer incidence before and after kidney transplantation. JAMA 2006, 296:2823-2831.
5. Engels E.A., Pfeiffer R.M., Fraumeni J.F., Kasiske B.L., Israni A.K., Snyder J.J., et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306:1891-1901.
6. Swerdlow S.H., Webber S.A., Chadburn A., Ferry J.A. Post-Transplant Lymphoproliferative Disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC, Lyon, France.
7. Ibrahim H.A., Naresh K.N. Posttransplant lymphoproliferative disorders. Adv. Hematol 2012, 2012:230173.
8. Smets F., Sokal E.M. Prevention and treatment for Epstein-Barr virus infection and related cancers. Recent Results Cancer Res 2014, 193:173-190.
9. Izadi M., Taheri S. Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: report from the PTLD. Int. survey. Ann. Transplant 2011, 16:39-47.
10. Piselli P., Serraino D., Segoloni G.P., Sandrini S., Piredda G.B., Scolari M.P., et al. Immunosuppression and Cancer Study Group. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur. J. Cancer 2013, 49:336-344.
11. Govantes M.A., Esteve A.F., Ramos M.T., Gracia De Guindo M.C., Sánchez L.F., Blanca M.A., et al. Incidence of post-transplantation lymphoproliferative disease in Andalusia (1990-2009). Transplant. Proc 2013, 45:3592-3594.
12. Yoon J.H., Lee S., Kim H.J., Lee J.W., Min W.S., Chung B.H., et al. Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation. Transpl. Int 2014, 27:721-732.
13. Quinlan S.C., Pfeiffer R.M., Morton L.M., Engels E.A. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am. J. Hematol 2011, 86:206-209.
14. Sampaio M.S., Cho Y.W., Shah T., Bunnapradist S., Hutchinson I.V. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol. Dial. Transplant 2012, 27:2971-2979.
15. Yoon S.O., Yu E., Cho Y.M., Suh C., Kim K.M., Han D.J., et al. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009. Clin. Transplant 2012, 26:67-73.
16. Marino D., Burra P., Boccagni P., Calabrese F., Canova F., Trentin C., et al. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience. Anticancer Res 2010, 30:2383-2391.
17. Ettorre G.M., Piselli P., Galatioto L., Rendina M., Nudo F., Sforza D., et al. De novo malignancies following liver transplantation: results from a multicentric study in central and southern Italy, 1990-2008. Transplant. Proc 2013, 45:2729-2732.
18. Mendizabal M., Marciano S., dos Santos Schraiber L., Zapata R., Quiros R., Zanotelli M.L., et al. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience. Clin. Transplant 2013, 27:469-477.
19. Lo R.C., Chan S.C., Chan K.L., Chiang A.K., Lo C.M., Ng I.O. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. J. Clin. Pathol 2013, 66:392-398.
20. Hsiao C.Y., Lee P.H., Ho C.M., Wu Y.M., Ho M.C., Hu R.H. Post-transplant malignancy in liver transplantation: a single center experience. Medicine (Baltimore) 2014, 93:e310.
21. Kataoka K., Seo S., Sugawara Y., Ota S., Imai Y., Takahashi T., et al. Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk. Lymphoma 2010, 51:1494-1501.
22. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.
23. Petrara M.R., Freguja R., Gianesin K., Zanchetta M., De Rossi A. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front. Microbiol 2013, 4:311.
24. San-Juan R., Comoli P., Caillard S., Moulin B., Hirsch H.H., Meylan P. ESCMID Study Group of Infection in Compromised Hosts. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin. Microbiol. Infect 2014, Suppl 7:109-118.
25. Caillard S., Porcher R., Provot F., Dantal J., Choquet S., Durrbach A., et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J. Clin. Oncol 2013, 31:1302-1309.
26. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun. Rev 2007, 7:96-101.
27. Khedmat H., Taheri S. Ultra-early onset post-transplantation lymphoproliferative disease. Saudi J. Kidney Dis. Transpl 2013, 24:1144-1152.
28. Michonneau D., Suarez F., Lambert J., Adam J., Brousse N., Canioni D., et al. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrol. Dial. Transplant 2013, 28:471-478.
29. Chan T.S., Hwang Y.Y., Gill H., Au W.Y., Leung A.Y., Tse E., et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin. Transplant 2012, 26:679-683.
30. Morton M., Coupes B., Roberts S.A., Klapper P.E., Byers R.J., Vallely P.J., et al. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients. Transplantation 2013, 95:470-478.
31. Chen M.R. Epstein-Barr virus, the immune system, and associated diseases. Front. Microbiol 2011, 2:5.
32. Dolcetti R., De Rossi A. Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications. Med. Res. Rev 2012, 32:233-253.
33. Terrin L., Dolcetti R., Corradini I., Indraccolo S., Dal Col J., Bertorelle R., et al. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int. J. Cancer 2007, 121:576-587.
34. Terrin L., Dal Col J., Rampazzo E., Zancai P., Pedrotti M., Ammirabile G., et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J. Virol 2008, 82:10175-10187.
35. Giunco S., Celeghin A., Gianesin K., Dolcetti R., Indraccolo S., De Rossi A. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death Dis 2015, 6:e1774.
36. Giunco S., Dolcetti R., Keppel S., Celeghin A., Indraccolo S., Dal Col J., et al. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B-cells: a basis for new therapies. Clin. Cancer Res 2013, 19:2036-2047.
37. Hong G.K., Gulley M.L., Feng W.H., et al. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol 2005, 79:13993-14003.
38. Draborg A.H., Duus K., Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin. Dev. Immunol 2012, 370516.
39. Hong G.K., Gulley M.L., Feng W.H., Delecluse H.J., Holley-Guthrie E., Kenney S.C. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J. Virol 2005, 79:13984-13992.
40. Hotchkiss R.S., Moldawer L.L. Parallels between cancer and infectious disease. N. Engl. J. Med 2014, 371:380-383.
41. Rieckmann P., Poli G., Fox C.H., Kehrl J.H., Fauci A.S. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J. Immunol 1991, 147:2922-2927.
42. Takeshita S., Breen E.C., Ivashchenko M., Nishanian P.G., Kishimoto T., Vredevoe D.L., et al. Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line. Cell. Immunol 1995, 165:234-242.
43. Mandl J.N., Barry A.P., Vanderford T.H., Kozyr N., Chavan R., Klucking S., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med 2008, 14:1077-1087.
44. Ambinder R.F., Bhatia K., Martinez-Maza O., Mitsuyasu R. Cancer biomarkers in HIV patients. Curr. Opin. HIV AIDS 2010, 5:531-537.
45. Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol. Biomarkers Prev 2011, 20:1303-1314.
46. Ladell K., Dorner M., Zauner L., Berger C., Zucol F., Bernasconi M., et al. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell. Microbiol 2007, 9:2055-2069.
47. Petrara M.R., Cattelan A.M., Zanchetta M., Sasset L., Freguja R., Gianesin K., et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J. Clin. Virol 2012, 53:195-200.
48. Kimura H., Ito Y., Suzuki R., Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev. Med. Virol 2008, 18:305-319.
49. Heslop H.E. How I treat EBV lymphoproliferation. Blood 2009, 114:4002-4008.
50. Yang J., Tao Q., Flinn I.W., Murray P.G., Post L.E., Ma H., et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000, 96:4055-4063.
51. Hopwood P.A., Brooks L., Parratt R., Hunt B.J., Bokhari M., Thomas J.A., et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002, 74:194-202.
52. van Esser J.W., Niesters H.G., Thijsen S.F., Meijer E., Osterhaus A.D., Wolthers K.C., et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br. J. Haematol 2001, 113:814-821.
53. Rowe D.T., Qu L., Reyes J., Jabbour N., Yunis E., Putnam P., et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J. Clin. Microbiol 1997, 35:1612-1615.
54. Green M., Cacciarelli T.V., Mazariegos G.V., Sigurdsson L., Qu L., Rowe D.T., et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998, 66:1641-1644.
55. Fellner M.D., Durand K., Correa M., Bes D., Alonio L.V., Teyssié A.R., et al. A semiquantitative PCR method (SQ-PCR) to measure Epstein-Barr virus (EBV) load: its application in transplant patients. J. Clin. Virol 2003, 28:323-330.
56. Baiocchi O.C., Colleoni G.W., Caballero O.L., Vettore A.L., Bulgarelli A., Dalbone M.A., et al. Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort. Leuk. Lymphoma 2005, 46:533-539.
57. Meerbach A., Wutzler P., Häfer R., Zintl F., Gruhn B. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J. Med. Virol 2008, 80:441-454.
58. Baldanti F., Rognoni V., Cascina A., Oggionni T., Tinelli C., Meloni F. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients. Virol. J. 2011, 8:421.
59. Bai X., Rogers B.B., Harkins P.C., Sommerauer J., Squires R., Rotondo K., et al. Predictive value of quantitative PCR-based viral burden analysis for eight human herpesviruses in pediatric solid organ transplant patients. J. Mol. Diagn 2000, 2:191-201.
60. Stevens S.J., Verschuuren E.A., Pronk I., van Der Bij W., Harmsen M.C., The T.H., et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001, 97:1165-1171.
61. Matsukura T., Yokoi A., Egawa H., Kudo T., Kawashima M., Hirata Y., et al. Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clin. Transplant 2002, 16:107-112.
62. Holman C.J., Karger A.B., Mullan B.D., Brundage R.C., Balfour H.H. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin. Transplant 2012, 26:741-747.
63. Cho Y.U., Chi H.S., Jang S., Park S.H., Park C.J. Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders. Am. J. Clin. Pathol 2014, 141:268-274.
64. Aalto S.M., Juvonen E., Tarkkanen J., Volin L., Haario H., Ruutu T., et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin. Infect. Dis 2007, 45:1305-1309.
65. Savoie A., Perpete C., Carpentier L., Joncas J., Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994, 83:2715-2722.
66. Lucas K.G., Filo F., Heilman D.K., Lee C.H., Emanuel D.J. Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Blood 1998, 92:3977-3978.
67. Funk G.A., Gosert R., Hirsch H.H. Viral dynamics in transplant patients: implications for disease. Lancet Infect. Dis 2007, 7:460-472. [Erratum in: Lancet Infect. Dis. 8 (2008) 600].
68. Abbate I., Zanchetta M., Gatti M., Gabrielli L., Zanussi S., Milia M.G., et al. Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients. J. Clin. Virol 2011, 50:224-229.
69. Ogha S., Kubo E., Nomura A., Takada H., Suga N., Ishii E., et al. Quantitative monitoring of circulating Epstein-Barr virus DNA for predicting the development of posttransplantation lymphoproliferative disease. Int. J. Hematol 2001, 73:323-326.
70. Kullberg-Lindh C., Ascher H., Saalman R., Olausson M., Lindh M. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction. Pediatr. Transplant 2006, 10:83-89.
71. Smets F., Sokal E.M. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr. Transplant 2002, 6:280-287.
72. Hatton O., Martinez O.M., Esquivel C.O. Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. Pediatr. Transplant 2012, 16:220-229.
73. Choquet S., Leblond V., Herbrecht R., Socié G., Stoppa A.M., Vandenberghe P., et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006, 107:3053-3057.
74. Elstrom R.L., Andreadis C., Aqui N.A., Ahya V.N., Bloom R.D., Brozena S.C., et al. Treatment of PTLD with rituximab or chemotherapy. Am. J. Transplant 2006, 6:569-576.
75. Gupta S., Fricker F.J., González-Peralta R.P., Slayton W.B., Schuler P.M., Dharnidharka V.R. Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr. Transplant 2010, 14:896-902.
76. Styczynski J., Einsele H., Gil L., Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl. Infect. Dis 2009, 11:383-392.
77. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat. Rev. Clin. Oncol 2012, 9:510-519.
78. Bollard C.M., Gottschalk S., Torrano V., Diouf O., Ku S., Hazrat Y., et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr Virus latent membrane proteins. J. Clin. Oncol 2014, 32:798-808.
79. McDiarmid S.V., Jordan S., Kim G.S., Toyoda M., Goss J.A., Vargas J.H., et al. Prevention and preemptive therapy of post-transplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998, 66:1604-1611.
80. Funch D.P., Walker A.M., Schneider G., Ziyadeh N.J., Pescovitz M.D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant 2005, 5:2894-2900.
81. Hierro L., Díez-Dorado R., Díaz C., De la Vega A., Frauca E., Camarena C., et al. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl 2008, 14:1185-1193.
82. Westphal E.M., Mauser A., Swenson J., Davis M.G., Talarico C.L., Kenney S.C. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res 1999, 59:1485-1491.
83. Feng W.H., Israel B., Raab-Traub N., Busson P., Kenney S.C. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002, 62:1920-1926.
84. Feng W.H., Cohen J.I., Fischer S., Li L., Sneller M., Goldbach-Mansky R., et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J. Natl Cancer Inst 2004, 96:1691-1702.
85. Tang W., Harmon P., Gulley M.L., Mwansambo C., Kazembe P.N., Martinson F., et al. Viral response to chemotherapy in endemic burkitt lymphoma. Clin. Cancer Res 2010, 16:2055-2064.
86. Moore S.M., Cannon J.S., Tanhehco Y.C., Hamzeh F.M., Ambinder R.F. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob. Agents Chemother 2001, 45:2082-2091.
87. Feng W.H., Kenney S.C. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006, 66:8762-8769.
88. Shirley C.M., Chen J., Shamay M., Li H., Zahnow C.A., Hayward S.D., et al. Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. Blood 2011, 117:6297-6303.
89. Perrine S.P., Hermine O., Small T., Suarez F., O'Reilly R., Boulad F., et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109:2571-2578.